MCID: ANG015
MIFTS: 54

Angioedema

Categories: Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Angioedema

MalaCards integrated aliases for Angioedema:

Name: Angioedema 12 75 55 6 44 15 17 72
Angioneurotic Oedema 12 33
Quincke's Edema 12 75
Angioneurotic Edema 12
Giant Urticaria 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1558
MeSH 44 D000799
NCIt 50 C112175
SNOMED-CT 68 41291007 82966003
ICD10 33 T78.3
UMLS 72 C0002994

Summaries for Angioedema

Disease Ontology : 12 A skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues.

MalaCards based summary : Angioedema, also known as angioneurotic oedema, is related to angioedema, hereditary, type i and acquired angioedema, and has symptoms including edema and peau d'orange. An important gene associated with Angioedema is F12 (Coagulation Factor XII), and among its related pathways/superpathways are Collagen chain trimerization and Peptide hormone metabolism. The drugs Enalapril and Enalaprilat have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and tongue.

Wikipedia : 75 Angioedema is an area of swelling of the lower layer of skin and tissue just under the skin or mucous... more...

Related Diseases for Angioedema

Diseases in the Angioedema family:

Angioedema, Hereditary, Type I Angioedema, Hereditary, Type Iii
Hereditary Angioedema Acquired Angioedema
Acquired Angioedema Type 1 Acquired Angioedema Type 2

Diseases related to Angioedema via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 504, show less)
# Related Disease Score Top Affiliating Genes
1 angioedema, hereditary, type i 34.7 SERPING1 F12
2 acquired angioedema 34.7 SERPING1 C1S
3 hereditary angioedema 32.9 XPNPEP2 SERPING1 KNG1 KLKB1 F12 C1S
4 c1 inhibitor deficiency 32.7 SERPING1 KNG1 KLKB1 C1S BDKRB2
5 allergic urticaria 30.8 SERPING1 KNG1
6 congestive heart failure 30.3 MME KNG1 ACE
7 hydrops, lactic acidosis, and sideroblastic anemia 30.1 SERPING1 PTGS2 PTGS1 KNG1 C1S
8 rheumatic disease 29.4 PTGS2 PTGS1 C1S
9 eosinophilia-myalgia syndrome 29.2 IL5 HNMT
10 proteasome-associated autoinflammatory syndrome 1 29.0 PTGS2 PTGS1 IL5
11 urticaria 28.7 SERPING1 PTGS2 PTGS1 LTC4S HNMT F12
12 hypertension, essential 28.4 MME KNG1 KLKB1 F12 BDKRB2 ACE
13 myocardial infarction 28.3 PTGS2 PTGS1 MME KNG1 ACE
14 angioedema, hereditary, type iii 12.8
15 angioedema induced by ace inhibitors 12.8
16 episodic angioedema with eosinophilia 12.6
17 non-histaminic angioedema 12.3
18 hereditary angioedema with normal c1inh 12.3
19 hereditary angioedema with c1inh deficiency 12.2
20 acquired angioedema type 1 12.2
21 acquired angioedema type 2 12.2
22 vibratory urticaria 12.2
23 plg-related hereditary angioedema with normal c1inh 12.1
24 angpt1-related hereditary angioedema with normal c1inh 12.1
25 acquired angioedema with c1inh deficiency 12.1
26 complement component 4, partial deficiency of 11.7
27 loiasis 11.5
28 carboxypeptidase n deficiency 11.3
29 netherton syndrome 11.2
30 hypereosinophilic syndrome 10.6
31 allergic hypersensitivity disease 10.6
32 exanthem 10.5
33 autoimmune disease 10.4
34 lupus erythematosus 10.4
35 vasculitis 10.4
36 food allergy 10.4
37 systemic lupus erythematosus 10.4
38 diarrhea 10.4
39 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
40 physical urticaria 10.3
41 lymphoproliferative syndrome 10.3
42 dysphagia 10.3
43 ige responsiveness, atopic 10.3
44 drug allergy 10.3
45 neurodermatitis 10.2
46 stroke, ischemic 10.2
47 lymphoma 10.2
48 contact dermatitis 10.2
49 cerebrovascular disease 10.2
50 peroneal neuropathy 10.2 MME CPN1
51 acute pancreatitis 10.2
52 glomerulonephritis 10.2
53 rhinitis 10.2
54 cholinergic urticaria 10.2
55 dermatitis 10.2
56 pancreatitis 10.2
57 thyroiditis 10.2
58 macroglossia 10.2
59 capillary leak syndrome 10.2
60 allergic contact dermatitis 10.2
61 systemic capillary leak syndrome 10.2
62 malignant essential hypertension 10.2 KNG1 KLKB1 ACE
63 renal hypertension 10.1 KNG1 KLKB1 ACE
64 disseminated intravascular coagulation 10.1
65 intussusception 10.1
66 cellulitis 10.1
67 crohn's disease 10.1
68 48,xyyy 10.1
69 hashimoto thyroiditis 10.1
70 allergic rhinitis 10.1
71 mastocytosis 10.1
72 alopecia 10.1
73 cold urticaria 10.1
74 cytokine deficiency 10.1
75 mastocytosis, cutaneous 10.1
76 osteomyelitis 10.1
77 pleurisy 10.1
78 intracranial aneurysm 10.1
79 visual epilepsy 10.1
80 extrinsic allergic alveolitis 10.1
81 myoclonus 10.1
82 seizure disorder 10.1
83 drug-induced lupus erythematosus 10.1 KLKB1 F12
84 lymphoma, hodgkin, classic 10.1
85 helicobacter pylori infection 10.1
86 lymphoma, non-hodgkin, familial 10.1
87 hypothyroidism 10.1
88 cheilitis 10.1
89 ischemia 10.1
90 skin disease 10.1
91 kidney disease 10.1
92 ileus 10.1
93 47,xyy 10.1
94 chronic tic disorder 10.0 IL5 F12
95 dermatomyositis 10.0
96 childhood type dermatomyositis 10.0
97 pemphigoid gestationis 10.0
98 epilepsy 10.0
99 fibrillary glomerulonephritis 10.0
100 neurofibromatosis, type ii 10.0
101 leukemia, chronic lymphocytic 10.0
102 thrombophilia due to thrombin defect 10.0
103 microvascular complications of diabetes 3 10.0
104 microvascular complications of diabetes 4 10.0
105 microvascular complications of diabetes 6 10.0
106 microvascular complications of diabetes 7 10.0
107 marginal zone b-cell lymphoma 10.0
108 cardiac arrest 10.0
109 lymphocytic leukemia 10.0
110 respiratory failure 10.0
111 graves' disease 10.0
112 vascular disease 10.0
113 hepatitis 10.0
114 dystonia 10.0
115 connective tissue disease 10.0
116 end stage renal failure 10.0
117 appendicitis 10.0
118 arthritis 10.0
119 fasciitis 10.0
120 leukemia, b-cell, chronic 10.0
121 coproporphyria, hereditary 10.0
122 cyclic neutropenia 10.0
123 vitiligo-associated multiple autoimmune disease susceptibility 6 10.0
124 aging 10.0
125 vitiligo-associated multiple autoimmune disease susceptibility 1 10.0
126 nasopharyngeal carcinoma 10.0
127 severe cutaneous adverse reaction 10.0
128 hereditary lymphedema 10.0
129 hemorrhagic cystitis 10.0
130 charcot-marie-tooth disease 10.0
131 tooth disease 10.0
132 erysipelas 10.0
133 neutropenia 10.0
134 leukemia 10.0
135 leiomyoma 10.0
136 telangiectasis 10.0
137 opisthorchiasis 10.0
138 renal tubular acidosis 10.0
139 cystitis 10.0
140 angiodysplasia 10.0
141 ludwig's angina 10.0
142 proliferative glomerulonephritis 10.0
143 lymphopenia 10.0
144 gastrointestinal system disease 10.0
145 pityriasis versicolor 10.0
146 amyloidosis 10.0
147 accessory pancreas 10.0
148 leukoplakia 10.0
149 spondylarthropathy 10.0
150 stevens-johnson syndrome/toxic epidermal necrolysis 10.0
151 rare systemic disease 10.0
152 periodic paralysis 10.0
153 erythema multiforme major 10.0
154 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.0
155 thyroid carcinoma 10.0
156 gastroesophageal reflux 10.0
157 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
158 familial mediterranean fever 10.0
159 myeloma, multiple 10.0
160 asthma 10.0
161 anxiety 10.0
162 erythema multiforme 10.0
163 inflammatory bowel disease 10.0
164 splenic marginal zone lymphoma 10.0
165 immunoglobulin alpha deficiency 10.0
166 esophagitis 10.0
167 adult-onset still's disease 10.0
168 panniculitis 10.0
169 pneumothorax 10.0
170 hepatitis c 10.0
171 hepatitis b 10.0
172 gastroenteritis 10.0
173 myopathy 10.0
174 adenoma 10.0
175 b-cell lymphoma 10.0
176 hyperthyroidism 10.0
177 peritonitis 10.0
178 pulmonary embolism 10.0
179 hemophilia 10.0
180 carcinoid syndrome 10.0
181 hypocomplementemic urticarial vasculitis 10.0
182 pik3ca-related overgrowth syndrome 10.0
183 aspirin resistance 9.9 PTGS2 PTGS1
184 active peptic ulcer disease 9.9 PTGS2 PTGS1
185 pfeiffer syndrome 9.9
186 spondyloarthropathy 1 9.9
187 atherosclerosis susceptibility 9.9
188 hepatocellular carcinoma 9.9
189 renal cell carcinoma, nonpapillary 9.9
190 rheumatoid arthritis 9.9
191 thrombophilia due to activated protein c resistance 9.9
192 anemia, autoimmune hemolytic 9.9
193 celiac disease 1 9.9
194 complement component 2 deficiency 9.9
195 eosinophilic fasciitis 9.9
196 myelofibrosis 9.9
197 myxedema 9.9
198 periodontitis, chronic 9.9
199 dermatitis, atopic 9.9
200 psoriatic arthritis 9.9
201 hypereosinophilic syndrome, idiopathic 9.9
202 intraocular pressure quantitative trait locus 9.9
203 membranous nephropathy 9.9
204 deficiency anemia 9.9
205 anaplastic large cell lymphoma 9.9
206 lymphoplasmacytic lymphoma 9.9
207 peripheral t-cell lymphoma 9.9
208 follicular lymphoma 9.9
209 aphasia 9.9
210 fish allergy 9.9
211 endometrial hyperplasia 9.9
212 parotitis 9.9
213 prostatic hypertrophy 9.9
214 hypoparathyroidism 9.9
215 heart disease 9.9
216 hypertensive heart disease 9.9
217 nephrotic syndrome 9.9
218 inflammatory spondylopathy 9.9
219 goiter 9.9
220 common variable immunodeficiency 9.9
221 hepatitis a 9.9
222 guillain-barre syndrome 9.9
223 gout 9.9
224 facial paralysis 9.9
225 toxic shock syndrome 9.9
226 cholecystitis 9.9
227 rectum cancer 9.9
228 enthesopathy 9.9
229 membranoproliferative glomerulonephritis 9.9
230 antiphospholipid syndrome 9.9
231 acute kidney failure 9.9
232 purpura 9.9
233 blepharochalasis 9.9
234 hemolytic anemia 9.9
235 conjunctivitis 9.9
236 complement deficiency 9.9
237 spondylitis 9.9
238 compartment syndrome 9.9
239 monoclonal gammopathy of uncertain significance 9.9
240 peptic ulcer disease 9.9
241 periodontitis 9.9
242 collagen disease 9.9
243 herpes simplex 9.9
244 macroglobulinemia 9.9
245 necrotizing fasciitis 9.9
246 stomatitis 9.9
247 irritable bowel syndrome 9.9
248 alopecia areata 9.9
249 acquired hemophilia 9.9
250 macrophage activation syndrome 9.9
251 papular urticaria 9.9
252 splenomegaly 9.9
253 raynaud phenomenon 9.9
254 depression 9.9
255 headache 9.9
256 recurrent acute pancreatitis 9.9
257 discoid lupus erythematosus 9.9
258 ulcerative colitis 9.8
259 hypoglycemia 9.8
260 atrial standstill 1 9.7
261 blepharochalasis and double lip 9.7
262 burkitt lymphoma 9.7
263 breast cancer 9.7
264 colorectal cancer 9.7
265 cardiac arrhythmia 9.7
266 carpal tunnel syndrome 9.7
267 cheilitis glandularis 9.7
268 major affective disorder 1 9.7
269 immunoglobulin a deficiency 1 9.7
270 hair whorl 9.7
271 periodic fever, familial, autosomal dominant 9.7
272 hypercholesterolemia, familial, 1 9.7
273 lipomatosis, multiple 9.7
274 migraine with or without aura 1 9.7
275 myositis 9.7
276 osteoporosis 9.7
277 pancreatitis, hereditary 9.7
278 pemphigus vulgaris, familial 9.7
279 pernicious anemia 9.7
280 protoporphyria, erythropoietic, 1 9.7
281 pulmonary hypertension, primary, 1 9.7
282 raynaud disease 9.7
283 scleroderma, familial progressive 9.7
284 small cell cancer of the lung 9.7
285 temporal arteritis 9.7
286 thrombocytopenic purpura, autoimmune 9.7
287 urticaria, aquagenic 9.7
288 varicose veins 9.7
289 alopecia universalis congenita 9.7
290 chiari malformation type ii 9.7
291 lung cancer 9.7
292 enterocolitis 9.7
293 immune deficiency disease 9.7
294 leprosy 3 9.7
295 myasthenia gravis 9.7
296 ocular motor apraxia 9.7
297 polycythemia vera 9.7
298 pulmonary alveolar microlithiasis 9.7
299 allan-herndon-dudley syndrome 9.7
300 fabry disease 9.7
301 arts syndrome 9.7
302 muscular dystrophy, duchenne type 9.7
303 androgen insensitivity, partial 9.7
304 gonadoblastoma 9.7
305 ataxia and polyneuropathy, adult-onset 9.7
306 kearns-sayre syndrome 9.7
307 gallbladder disease 1 9.7
308 yemenite deaf-blind hypopigmentation syndrome 9.7
309 gastrointestinal stromal tumor 9.7
310 anorexia nervosa 9.7
311 pulmonary disease, chronic obstructive 9.7
312 endometrial cancer 9.7
313 major depressive disorder 9.7
314 granulomatosis with polyangiitis 9.7
315 hepatitis c virus 9.7
316 bone mineral density quantitative trait locus 8 9.7
317 major affective disorder 8 9.7
318 major affective disorder 9 9.7
319 antithrombin iii deficiency 9.7
320 bone mineral density quantitative trait locus 15 9.7
321 alpha-1-antitrypsin deficiency 9.7
322 mannose-binding lectin deficiency 9.7
323 leptin deficiency or dysfunction 9.7
324 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 9.7
325 immunodeficiency, common variable, 10 9.7
326 autoimmune lymphoproliferative syndrome, type v 9.7
327 hyperlipoproteinemia, type iii 9.7
328 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.7
329 chlamydia pneumonia 9.7
330 cutaneous lupus erythematosus 9.7
331 small cell carcinoma 9.7
332 mantle cell lymphoma 9.7
333 metabolic acidosis 9.7
334 oromandibular dystonia 9.7
335 sleep apnea 9.7
336 alexithymia 9.7
337 pain agnosia 9.7
338 colitis 9.7
339 crohn's colitis 9.7
340 atrial fibrillation 9.7
341 inguinal hernia 9.7
342 penicillin allergy 9.7
343 purpura fulminans 9.7
344 pleomorphic lipoma 9.7
345 ehrlichiosis 9.7
346 mumps 9.7
347 sialadenitis 9.7
348 siderosis 9.7
349 bacterial infectious disease 9.7
350 tonsillitis 9.7
351 common cold 9.7
352 nasopharyngitis 9.7
353 pre-eclampsia 9.7
354 filariasis 9.7
355 chlamydia 9.7
356 adult respiratory distress syndrome 9.7
357 pulmonary edema 9.7
358 horner's syndrome 9.7
359 polycystic ovary syndrome 9.7
360 hyperandrogenism 9.7
361 iron deficiency anemia 9.7
362 coronary artery anomaly 9.7
363 aseptic meningitis 9.7
364 pancytopenia 9.7
365 trichuriasis 9.7
366 hemolytic-uremic syndrome 9.7
367 miller fisher syndrome 9.7
368 dilated cardiomyopathy 9.7
369 cholestasis 9.7
370 eclampsia 9.7
371 dental fluorosis 9.7
372 amenorrhea 9.7
373 peptic esophagitis 9.7
374 primary angle-closure glaucoma 9.7
375 bacteriuria 9.7
376 papilledema 9.7
377 echinococcosis 9.7
378 nodular nonsuppurative panniculitis 9.7
379 thrombocytopenia 9.7
380 renovascular hypertension 9.7
381 mental depression 9.7
382 lymphadenitis 9.7
383 duodenal ulcer 9.7
384 viral hepatitis 9.7
385 melanoma 9.7
386 hypogonadism 9.7
387 exostosis 9.7
388 acute maxillary sinusitis 9.7
389 maxillary sinusitis 9.7
390 focal epilepsy 9.7
391 transient cerebral ischemia 9.7
392 pharyngitis 9.7
393 dyspepsia 9.7
394 colon adenocarcinoma 9.7
395 iron metabolism disease 9.7
396 macrocytic anemia 9.7
397 protein s deficiency 9.7
398 thrombophilia 9.7
399 opiate dependence 9.7
400 agammaglobulinemia 9.7
401 phimosis 9.7
402 cryoglobulinemia 9.7
403 periarthritis 9.7
404 iga glomerulonephritis 9.7
405 adenocarcinoma 9.7
406 cystic lymphangioma 9.7
407 lipid metabolism disorder 9.7
408 bipolar disorder 9.7
409 mood disorder 9.7
410 carotid artery thrombosis 9.7
411 mast cell neoplasm 9.7
412 extramedullary plasmacytoma 9.7
413 plasmacytoma 9.7
414 intestinal pseudo-obstruction 9.7
415 gastritis 9.7
416 eosinophilic gastroenteritis 9.7
417 liver disease 9.7
418 systemic scleroderma 9.7
419 tinea favosa 9.7
420 milk allergy 9.7
421 folliculitis 9.7
422 macular retinal edema 9.7
423 clear cell renal cell carcinoma 9.7
424 extracutaneous mastocytoma 9.7
425 brain edema 9.7
426 elephantiasis 9.7
427 thyroid gland disease 9.7
428 aortitis 9.7
429 paraphimosis 9.7
430 schizoaffective disorder 9.7
431 peripheral nervous system disease 9.7
432 bronchitis 9.7
433 viral encephalitis 9.7
434 juvenile rheumatoid arthritis 9.7
435 infiltrating lipoma 9.7
436 dermatographia 9.7
437 hypogonadotropism 9.7
438 diverticulitis 9.7
439 chronic kidney disease 9.7
440 myocarditis 9.7
441 cataract 9.7
442 polycythemia 9.7
443 intestinal obstruction 9.7
444 influenza 9.7
445 chickenpox 9.7
446 eating disorder 9.7
447 neuropathy 9.7
448 chorioretinitis 9.7
449 evans' syndrome 9.7
450 peliosis hepatis 9.7
451 gas gangrene 9.7
452 achalasia 9.7
453 pemphigus 9.7
454 speech disorder 9.7
455 priapism 9.7
456 lymphangitis 9.7
457 carotid artery dissection 9.7
458 exophthalmos 9.7
459 epiglottitis 9.7
460 allergic asthma 9.7
461 intracranial hypertension 9.7
462 fatty liver disease 9.7
463 meningitis 9.7
464 dacryoadenitis 9.7
465 bronchiectasis 9.7
466 encephalitis 9.7
467 tenosynovitis 9.7
468 polyarteritis nodosa 9.7
469 muscular dystrophy 9.7
470 dacryocystitis 9.7
471 sickle cell disease 9.7
472 acute respiratory distress syndrome 9.7
473 autoimmune progesterone dermatitis 9.7
474 broken heart syndrome 9.7
475 central serous chorioretinopathy 9.7
476 chiari malformation 9.7
477 complement component deficiency 9.7
478 congenital extrahepatic portosystemic shunt 9.7
479 cutaneous mastocytoma 9.7
480 eosinophilic enteropathy 9.7
481 eosinophilic granulomatosis with polyangiitis 9.7
482 granulocytopenia 9.7
483 hansen's disease 9.7
484 hereditary antithrombin deficiency 9.7
485 idiopathic edema 9.7
486 lymphomatoid granulomatosis 9.7
487 mallory-weiss syndrome 9.7
488 mast cell activation syndrome 9.7
489 periodontal ehlers-danlos syndrome 9.7
490 scleromyxedema 9.7
491 autonomic dysfunction 9.7
492 chronic pain 9.7
493 hypertonia 9.7
494 syncope 9.7
495 tremor 9.7
496 subacute cutaneous lupus erythematosus 9.7
497 b-cell non-hodgkin lymphoma 9.7
498 progressive muscular dystrophy 9.7
499 acute liver failure 9.7
500 lymphedema 9.7
501 rare surgical neurologic disease 9.7
502 solar urticaria 9.7
503 autoinflammatory syndrome 9.7
504 morphine dependence 9.4 PTGS2 PTGS1

Graphical network of the top 20 diseases related to Angioedema:



Diseases related to Angioedema

Symptoms & Phenotypes for Angioedema

UMLS symptoms related to Angioedema:


edema, peau d'orange

Drugs & Therapeutics for Angioedema

DrugBank drugs 16 :

(showing 5, show less)
# Drug Name Indication DrugBank ID
1 Carbinoxamine For symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, as well as allergic conjunctivitis caused by foods and inhaled allergens. Also for the relief of allergic reactions to blood or plasma, and the symptomatic management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. DB00748
2 Clemastine For the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation. Also for the management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Used as self-medication for temporary relief of symptoms associated with the common cold. DB00283
3 Dexchlorpheniramine maleate Dexchlorpheniramine can be used in the treatment of perennial and seasonal allergic rhinitis, vasomotor rhiniti, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, and dermographism. DB09555
4 Diphenhydramine Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insomnia, pruritis, urticaria, insect bites/stings, allergic rashes, and nausea [L5263, L5266, L5269, F3379, A174541]. Additionally, when the use of oral diphenhydramine is impractical, there are also prescription-only formulations such as diphenhydramine injection products that are effective in adults and pediatric patients (other than premature infants and neonates) for: i) the amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated [F3352]; ii) the active treatment of motion sickness [F3352]; and iii) use in parkinsonism when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents [F3352]. DB01075
5 Epinephrine Epinephrine injection is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Injectable epinephrine is intended for immediate/urgent administration in patients, who are found to be at increased risk for anaphylaxis, including individuals with a history of anaphylaxis. Selection of the appropriate dosage strength is determined according to body weight [FDA label]. Epinephrine's cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock [F1247]. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics [F1247]. In addition to the above, epinephrine is used as an over the counter (OTC) agent for the intermittent symptoms of asthma, such as wheezing, tightness of chest and shortness of breath [F2131]. It is also used for the maintenance of mydriasis during intraocular surgery [L4825]. DB00668

Drugs for Angioedema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 270, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
2
Enalaprilat Approved Phase 4 76420-72-9 6917719
3
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
5
Methadone Approved, Illicit Phase 4 76-99-3 4095
6
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
7
Azithromycin Approved Phase 4 83905-01-5 447043 55185
8
Ethanol Approved Phase 4 64-17-5 702
9
Ramipril Approved Phase 4 87333-19-5 5362129
10
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
11
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
12
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
13
Budesonide Approved Phase 4 51333-22-3 63006 5281004
14
Omalizumab Approved, Investigational Phase 4 242138-07-4
15
Ofloxacin Approved Phase 4 82419-36-1 4583
16
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
17
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
18
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
19
Icatibant Approved, Investigational Phase 4 138614-30-9, 130308-48-4 71364
20
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
21
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
22
Bradykinin Investigational Phase 4 58-82-2 439201
23 Antiviral Agents Phase 4
24 Protective Agents Phase 4
25 Antioxidants Phase 4
26 N-monoacetylcystine Phase 4
27 Narcotics Phase 4
28 Free Radical Scavengers Phase 4
29 Antidotes Phase 4
30 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
31 Expectorants Phase 4
32 Antitussive Agents Phase 4
33 Antacids Phase 4
34 Proton Pump Inhibitors Phase 4
35 Anti-Ulcer Agents Phase 4
36 Anti-Inflammatory Agents Phase 4
37 Peripheral Nervous System Agents Phase 4
38 Hormones Phase 4
39 Hormone Antagonists Phase 4
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
41 glucocorticoids Phase 4
42 Histamine H1 Antagonists, Non-Sedating Phase 4
43 Cholinergic Agents Phase 4
44 Cholinergic Antagonists Phase 4
45 Autonomic Agents Phase 4
46 Bronchodilator Agents Phase 4
47 Antibodies Phase 4
48 Immunoglobulins Phase 4
49 Respiratory System Agents Phase 4
50 Anti-Asthmatic Agents Phase 4
51 gamma-Globulins Phase 4
52 Immunoglobulins, Intravenous Phase 4
53 Rho(D) Immune Globulin Phase 4
54 Antibiotics, Antitubercular Phase 4
55 Renal Agents Phase 4
56 Anti-Infective Agents, Urinary Phase 4
57 Cytochrome P-450 Enzyme Inhibitors Phase 4
58 Antitubercular Agents Phase 4
59 Topoisomerase Inhibitors Phase 4
60 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
61 Central Nervous System Depressants Phase 4
62 Analgesics, Opioid Phase 4
63 Anesthetics, Local Phase 4
64 Anesthetics Phase 4
65 HIV Protease Inhibitors Phase 4
66
protease inhibitors Phase 4
67 Angiotensin-Converting Enzyme Inhibitors Phase 4
68 Kininogens Phase 4
69 cysteine Phase 4
70 Vasodilator Agents Phase 4
71 Bradykinin B2 Receptor Antagonists Phase 4
72 Bradykinin Receptor Antagonists Phase 4
73
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
74
Iron Approved, Experimental Phase 2, Phase 3 15438-31-0, 7439-89-6 23925 27284
75
Deferasirox Approved, Investigational Phase 2, Phase 3 201530-41-8 5493381
76
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
77
Deferoxamine Approved, Investigational Phase 2, Phase 3 70-51-9 2973
78
tannic acid Approved Phase 3 1401-55-4
79
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
80
Tranexamic Acid Approved Phase 3 1197-18-8 5526
81
Atenolol Approved Phase 3 29122-68-7 2249
82
Losartan Approved Phase 2, Phase 3 114798-26-4 3961
83
Azilsartan medoxomil Approved, Investigational Phase 3 863031-21-4
84
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
85
Levocetirizine Approved Phase 3 130018-77-8 1549000
86
Cortisone Experimental Phase 3 53-06-5 222786
87 Micronutrients Phase 2, Phase 3
88 Trace Elements Phase 2, Phase 3
89 Nutrients Phase 2, Phase 3
90 Antineoplastic Agents, Phytogenic Phase 3
91 Albumin-Bound Paclitaxel Phase 3
92 Tubulin Modulators Phase 3
93 Antimitotic Agents Phase 3
94 Liver Extracts Phase 2, Phase 3
95 Siderophores Phase 2, Phase 3
96 Iron Chelating Agents Phase 2, Phase 3
97 Pharmaceutical Solutions Phase 3
98 Kallikreins Phase 3
99 Plasma Kallikrein Phase 3
100 Coagulants Phase 3
101 Passionflower Phase 3
102 Fibrinolytic Agents Phase 3
103 Antifibrinolytic Agents Phase 3
104 Hemostatics Phase 3
105 Adrenergic beta-Antagonists Phase 3
106 Adrenergic Antagonists Phase 3
107 Anti-Arrhythmia Agents Phase 2, Phase 3
108 Adrenergic beta-1 Receptor Antagonists Phase 3
109 Antibodies, Monoclonal Phase 3
110 Antineoplastic Agents, Hormonal Phase 3
111
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
112
Danazol Approved Phase 2 17230-88-5 28417
113
Racepinephrine Approved Phase 2 329-65-7 838
114
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
115
Minocycline Approved, Investigational Phase 1, Phase 2 10118-90-8 5281021
116
Azathioprine Approved Phase 1, Phase 2 446-86-6 2265
117
Amphotericin B Approved, Investigational Phase 2 1397-89-3 14956 5280965
118
Rifaximin Approved, Investigational Phase 2 80621-81-4 46783403 6436173
119
Gemcitabine Approved Phase 2 95058-81-4 60750
120
Angiotensin II Approved, Investigational Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
121
Valsartan Approved, Investigational Phase 2 137862-53-4 60846
122
Histamine Approved, Investigational Phase 2 51-45-6 774
123
Cyproheptadine Approved Phase 2 129-03-3 2913
124 Fertility Agents Phase 2
125 Antifungal Agents Phase 1, Phase 2
126 Cyclosporins Phase 1, Phase 2
127 Calcineurin Inhibitors Phase 1, Phase 2
128 Estrogens Phase 2
129 Selective Estrogen Receptor Modulators Phase 2
130 Estrogen Receptor Modulators Phase 2
131 Estrogen Receptor Antagonists Phase 2
132 Estrogen Antagonists Phase 2
133 Epinephryl borate Phase 2
134 Sympathomimetics Phase 2
135 Adrenergic beta-Agonists Phase 2
136 Mydriatics Phase 2
137 Vasoconstrictor Agents Phase 2
138 Liposomal amphotericin B Phase 2
139 Antiparasitic Agents Phase 2
140 Anthelmintics Phase 2
141 Antiprotozoal Agents Phase 2
142 Antimony Sodium Gluconate Phase 2
143 Antineoplastic Agents, Immunological Phase 2
144 Plasminogen Phase 2
145 Antihypertensive Agents Phase 2
146 Antimetabolites Phase 2
147 Antimetabolites, Antineoplastic Phase 2
148 Natriuretic Peptide, Brain Phase 2
149 Natriuretic Agents Phase 2
150 Angiotensinogen Phase 2
151 Angiotensin Receptor Antagonists Phase 2
152 Angiotensin II Type 1 Receptor Blockers Phase 2
153 Giapreza Phase 2
154 LCZ 696 Phase 2
155 Gastrointestinal Agents Phase 2
156 Histamine Antagonists Phase 2
157
Histamine Phosphate Phase 2 51-74-1 65513
158 Anti-Allergic Agents Phase 2
159 Histamine H1 Antagonists Phase 2
160 Dermatologic Agents Phase 2
161 Serotonin Agents Phase 2
162 Serotonin Antagonists Phase 2
163 Antipruritics Phase 2
164
Serotonin Investigational, Nutraceutical Phase 2 50-67-9 5202
165
Oxandrolone Approved, Investigational Phase 1 53-39-4 5878
166
Digoxin Approved Phase 1 20830-75-5 30322 2724385
167
Omeprazole Approved, Investigational, Vet_approved Phase 1 73590-58-6 4594
168
Dextromethorphan Approved Phase 1 125-71-3 5360696 5362449
169
Midazolam Approved, Illicit Phase 1 59467-70-8 4192
170
Tolbutamide Approved, Investigational Phase 1 64-77-7 5505